Table 2.

Hazard ratios and 95% confidence intervals for new-onset ischemic heart diseases according to hepatic steatosis and hemoglobin.

		Group 1	Group 2	Group 3	Group 4	Group 5	P for trend
		No hepatic steatosis	Mild hepatic steatosis only	Mild hepatic steatosis + high Hb	Severe hepaticsteatosis only	Severe HS + high Hb
New cases of ischemic heart disease, n		177	56	24	44	29
Mean follow-up, years		2.4 ± 1.1	2.2 ± 1.1	2.4 ± 1.1	2.4 ± 1.1	2.5 ± 1.1
Pearson-years of follow-up		28,471	5,593	2,370	2,996	1,889
Incidence rate/1,000 person -years		6.2	10.0	10.1	14.7	15.4
Model 1	HR (95% CI)	1.00 (reference)	1.22 (0.90–1.65)	1.46 (0.95–2.23)	1.89 (1.35–2.65)	2.11 (1.42–3.13)	<0.001
	P-value		0.204	0.083	<0.001	<0.001
Model 2	HR (95% CI)	1.00 (reference)	1.11 (0.80–1.98)	1.23 (0.76–1.98)	1.70 (1.16–2.48)	2.00 (1.29–3.10)	0.008
	P-value		0.534	0.404	0.006	0.001
Model 3	HR (95% CI)	1.00 (reference)	1.11 (0.80–1.55)	1.23 (0.76–1.98)	1.75 (1.20–2.55)	2.00 (1.29–3.11)	0.005
	P-value		0.544	0.408	0.003	0.002
Model 4	HR (95% CI)	1.00 (reference)	1.04 (0.75–1.46)	1.14 (0.70–1.85)	1.58 (1.08–2.32)	1.79 (1.15–2.80)	0.039
	P-value		0.806	0.591	0.019	0.010

Model 1: adjusted for age and sex.

Model 2: adjusted for age, sex, body mass index, smoking status, alcohol intake, and physical activity.

Model 3: adjusted for age, sex, obesity, smoking status, alcohol intake, physical activity, mean arterial blood pressure, fasting plasma glucose, total cholesterol, and high-sensitivity C-reactive protein level.

Model 4: adjusted for age, sex, body mass index, smoking status, alcohol intake, physical activity, mean arterial blood pressure, fasting plasma glucose, total cholesterol, and high-sensitivity C-reactive protein level.